Loading clinical trials...
Loading clinical trials...
A Phase 3, Multicenter Study With a 36-Week Open-Label Period Followed by a Randomized Double-Blind Withdrawal Period From Week 36 to Week 104 to Evaluate the Long-Term Efficacy and Safety of Ixekizumab (LY2439821) 80 mg Every 2 Weeks in Biologic Disease-Modifying Antirheumatic Drug-Naive Patients With Active Psoriatic Arthritis
Conditions
Interventions
Ixekizumab
Placebo
Locations
106
United States
Arizona Arthritis & Rheumatology Research
Glendale, Arizona, United States
Arizona Arthritis & Rheumatology Research, PLLC
Mesa, Arizona, United States
Arizona Arthritis Research, PLC
Phoenix, Arizona, United States
University of California, Davis - Health Systems
Sacramento, California, United States
East Bay Rheumatology Medical Group
San Leandro, California, United States
Arthritis & Osteoporosis Treatment Center, PA
Orange Park, Florida, United States
Start Date
September 14, 2015
Primary Completion Date
October 30, 2018
Completion Date
October 30, 2018
Last Updated
November 15, 2019
NCT07486960
NCT07536529
NCT07295509
NCT07286058
NCT06100744
NCT04402086
Lead Sponsor
Eli Lilly and Company
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions